HealthcareServices

Chronic Idiopathic Urticaria Treatment Market Trends and Insights: Global Forecast to 2030

March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the chronic idiopathic urticaria treatment market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Chronic Idiopathic Urticaria Treatment Market covering 2026–2035?

The chronic idiopathic urticaria treatment market has experienced robust expansion in recent years. This market is projected to expand from $7.24 billion in 2025 to $7.89 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 9.0%. Historically, this growth can be ascribed to several factors, including a rise in chronic urticaria diagnoses, the presence of second-line antihistamine therapies, the implementation of stepwise treatment protocols, the proliferation of allergy specialty clinics, and the increasing application of immunomodulatory drugs.

The chronic idiopathic urticaria treatment market size is projected to experience robust expansion over the coming years. By 2030, it is expected to reach $11.23 billion, growing at a compound annual growth rate (CAGR) of 9.2%. This anticipated growth is influenced by factors such as an escalating demand for biologic treatment solutions, an increasing emphasis on personalized immunology care, the proliferation of digital tools for disease management, rising investments in innovative urticaria therapies, and enhanced patient awareness alongside improved treatment adherence. Significant developments during this forecast period include the expanding adoption of biologic therapies for refractory patients, a greater utilization of personalized treatment pathways, the increasing integration of digital tools for symptom monitoring, a wider availability of injectable treatment options, and a heightened focus on achieving long-term disease control.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33064&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Chronic Idiopathic Urticaria Treatment Market?

The chronic idiopathic urticaria treatment market is anticipated to expand due to an escalating emphasis on biologics. These biologics are therapeutic agents sourced from living organisms or their constituents, designed to address particular immune system pathways in disease management. The heightened focus on biologics stems from progress in biotechnology and immunology, facilitating the creation of more precise and effective therapies that target the root causes of immune-mediated conditions, rather than simply alleviating symptoms. Specifically, biologics target the fundamental immune pathways and mast cell activation linked to chronic idiopathic urticaria, thus transforming treatment approaches and offering patients improved, sustained symptom management. A notable example is that the 2023 WHO Essential Medicines List, as reported by the World Health Organization (WHO) in February 2025, a Switzerland-based intergovernmental organization, features 81 biologic therapies, accounting for over 15% of all medicines on the list. Consequently, this elevated focus on biologics is a key driver for the growth within the chronic idiopathic urticaria treatment market.

What Segments Are Identified Within The Structure Of The Chronic Idiopathic Urticaria Treatment Market?

The chronic idiopathic urticaria treatment market covered in this report is segmented –

1) By Types: Tablets; Capsules; Creams; Lotions; Injections

2) By Drug Class: Antihistamines; Corticosteroids; Leukotriene Receptor Antagonists; Immunosuppressants; Biologic Therapies; Other Drug Class

3) By Route Of Administration: Oral; Injectable; Topical

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Tablets: Immediate Release Tablets; Extended Release Tablets; Enteric Coated Tablets; Chewable Tablets; Orally Disintegrating Tablets

2) By Capsules: Hard Gelatin Capsules; Soft Gelatin Capsules; Sustained Release Capsules; Delayed Release Capsules

3) By Creams: Medicated Topical Creams; Anti Inflammatory Creams; Antifungal Creams; Antibacterial Creams; Moisturizing Therapeutic Creams

4) By Lotions: Medicated Therapeutic Lotions; Anti Inflammatory Lotions; Antiseptic Lotions; Moisturizing Lotions; Specialty Dermatological Lotions

5) By Injections: Intravenous Injections; Intramuscular Injections; Subcutaneous Injections; Pre Filled Syringe Injections; Auto Injector Based Injections

Which Trends Are Guiding The Evolution Of The Chronic Idiopathic Urticaria Treatment Market?

Major companies within the chronic idiopathic urticaria treatment market are increasingly focusing on developing innovative products, such as monoclonal antibody therapies, to offer targeted and long-lasting relief for patients who do not respond to standard treatments. These biologic drugs are specifically engineered to target immune system components like immunoglobulin E (IgE) or other inflammatory mediators that trigger chronic hives, providing a more precise action compared to traditional antihistamines or corticosteroids. For instance, in September 2025, Celltrion Inc., a biopharmaceutical company based in South Korea, launched Omriclo, an omalizumab biosimilar, in Norway. This product contains the same active monoclonal antibody as Xolair, functions by neutralizing circulating IgE, and is administered via subcutaneous injection. Its distinguishing features include a first-mover advantage in Europe, improved accessibility through local distribution channels, and potential cost savings for healthcare systems. It is designed for patients with chronic idiopathic urticaria who remain symptomatic despite standard therapy, offering a biologic alternative to conventional treatments and aiming for better symptom management, reduced frequency of flare-ups, and the potential to enhance overall quality of life by minimizing reliance on long-term antihistamine or corticosteroid use.

Which Major Firms Are Strengthening Their Position In The Chronic Idiopathic Urticaria Treatment Market?

Major companies operating in the chronic idiopathic urticaria treatment market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG., AstraZeneca PLC, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Incyte Corporation, Dr. Reddy’s Laboratories Ltd., Celltrion Inc., Yuhan Corporation, Kiniksa Pharmaceuticals Ltd., Celldex Therapeutics Inc., Septerna Therapeutics Inc., Carna Biosciences Inc., United BioPharma Inc., Recludix Pharma Inc., Jasper Therapeutics Inc., Evommune Inc., ARS Pharmaceuticals Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chronic-idiopathic-urticaria-treatment-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Chronic Idiopathic Urticaria Treatment Market?

North America was the largest region in the chronic idiopathic urticaria treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic idiopathic urticaria treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chronic Idiopathic Urticaria Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33064&type=smp

Browse Through More Reports Similar to the Global Chronic Idiopathic Urticaria Treatment Market 2026, By The Business Research Company

Chronic Spontaneous Urticaria Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Allergic Rhinitis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergic-rhinitis-drugs-global-market-report

Allergy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795